Science Explorer Back to mapMap
Institution · Hexal (Germany)

Most cited papers from Hexal (Germany)

What are the most cited papers from Hexal (Germany)?

The most cited paper from Hexal (Germany) is "Tannins: Current knowledge of food sources, intake, bioavailability and biological effects" (José C. E. Serrano, Riitta Puupponen‐Pimiä, Andreas Dauer et al., 2009), with 810 citations. Next come "Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development" (354) and "Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood" (301).

Showing 50 of 60 papers. Every paper with more than 28 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Tannins: Current knowledge of food sources, intake, bioavailability and biological effects José C. E. Serrano, Riitta Puupponen‐Pimiä, Andreas Dauer et al. · Molecular Nutrition & Food Research 12 May 2009 810
2 Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development John den Engelsman, Patrick Garidel, Ronald A. Smulders et al. · Pharmaceutical Research Open access 22 Oct 2010 354
3 Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood ROBERT D. ROSENBERG, Ralf Gertler, Jan Friederichs et al. · Cytometry Open access 26 Nov 2002 301
4 The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity Antibodies Christine Rothe, Stefanie Urlinger, Corinna Löhning et al. · Journal of Molecular Biology 14 Jan 2008 248
5 Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity Andreas Seidl, Otmar Hainzl, Marleen Richter et al. · Pharmaceutical Research Open access 17 Nov 2011 204
6 The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis Christopher E.M. Griffiths, Diamant Thaçi, Sascha Gerdes et al. · British Journal of Dermatology Open access 20 Jan 2017 183
7 Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab Jan Marinus Visser, Isabel Feuerstein, Thomas Stangler et al. · BioDrugs Open access 6 May 2013 183
8 Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches Andrew Blauvelt, J.‐P. Lacour, Joseph F. Fowler et al. · British Journal of Dermatology 19 Jun 2018 153
9 Cloning and expression of a cDNA encoding betanidin 5‐O‐glucosyltransferase, a betanidin‐ and flavonoid‐specific enzyme with high homology to inducible glucosyltransferases from the Solanaceae Thomas Vogt, Rudi Grimm, Dieter Strack · The Plant Journal Open access Sep 1999 146
10 Shedding of glycan‐modifying enzymes by signal peptide peptidase‐like 3 (SPPL3) regulates cellular N‐glycosylation Matthias Voß, Ulrike Künzel, Fabian Higel et al. · The EMBO Journal Open access 29 Oct 2014 111
11 Conformational processing of oncogenic v-Src kinase by the molecular chaperone Hsp90 Edgar E. Boczek, Lasse G. Reefschläger, Marco Dehling et al. · Proceedings of the National Academy of Sciences Open access 8 Jun 2015 87
12 Ten years of biosimilars in Europe: development and evolution of the regulatory pathways Martin Schiestl, Markus Zabransky, Fritz Sörgel · Drug Design Development and Therapy Open access May 2017 84
13 Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study Wojciech J. Jurczak, Ilídia Moreira, Govind Babu Kanakasetty et al. · The Lancet Haematology Open access 14 Jul 2017 82
14 Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon et al. · Annals of Oncology Open access 30 Jun 2015 81
15 Multiple switches between GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study Sascha Gerdes, Diamant Thaçi, Christopher E.M. Griffiths et al. · Journal of the European Academy of Dermatology and Venereology Open access 28 Sep 2017 76
16 Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support Gary H. Lyman, Lillian C. Yau, Roumen Nakov et al. · Annals of Oncology Open access 5 Aug 2018 67
17 A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis Josef S Smolen, Stanley B. Cohen, Hans‐Peter Tony et al. · Annals of the Rheumatic Diseases Open access 22 Jun 2017 65
18 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( Part 3 –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays) Bart Corsaro et al. · Bioanalysis Open access 3 Feb 2021 63
19 The Epidemiology of Acute Liver Failure Nina Weiler, Andreas Schlotmann, Andreas Anton Schnitzbauer et al. · Deutsches Ärzteblatt international Open access 17 Jan 2020 63
20 Maintaining consistent quality and clinical performance of biopharmaceuticals William C. Lamanna, Johann Holzmann, Hillel P. Cohen et al. · Expert Opinion on Biological Therapy Open access 29 Dec 2017 62
21 Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals Fabian Higel, Uwe M. Demelbauer, Andreas Seidl et al. · Analytical and Bioanalytical Chemistry Open access 30 Jan 2013 62
22 A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy Stanley B. Cohen, Rieke Alten, Hideto Kameda et al. · Arthritis Research & Therapy Open access 27 Jul 2018 60
23 N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance Fabian Higel, Theresa Sandl, Chi-Ya Kao et al. · European Journal of Pharmaceutics and Biopharmaceutics Open access 21 Mar 2019 55
24 Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics Fritz Sörgel, Arnd Schwebig, Johann Holzmann et al. · BioDrugs Open access Apr 2015 54
25 Supportive care in patients with cancer during the COVID-19 pandemic Matti Aapro, Gary H. Lyman, Carsten Bokemeyer et al. · ESMO Open Open access 5 Jan 2021 53
26 A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis Nurlan Dauletbaev, P.-A. Fischer, B Aulbach et al. · European journal of medical research Open access 12 Aug 2009 51
27 Fixed‐dose vs free‐dose combinations for the management of hypertension—An analysis of 81 958 patients Peter Bramlage, Stefanie Schmidt, Helen M. Sims · Journal of Clinical Hypertension Open access 19 Feb 2018 50
28 Quantum Shuttle: traffic navigation with Quantum computing Sheir Yarkoni, Florian Neukart, Eliane Moreno Gomez Tagle et al. Conference paperOpen access 13 Nov 2020 47
29 Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars Kristof Vandekerckhove, Andreas Seidl, Hiten J. Gutka et al. · The AAPS Journal Open access 10 May 2018 47
30 Penetration of Cefaclor Into the Interstitial Space Fluid of Skeletal Muscle and Lung Tissue in Rats Amparo de la Penña, Teresa Dalla Costa, James D. Talton et al. · Pharmaceutical Research Sep 2001 47
31 Biowaiver Monographs for Immediate Release Solid Oral Dosage forms: Metoclopramide Hydrochloride Andrea Stosik, Hans E. Junginger, Sabine Kopp et al. · Journal of Pharmaceutical Sciences 12 Feb 2008 46
32 Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013 Antônio da Silva, Ulrich O. Kronthaler, Vera Koppenburg et al. · Leukemia & lymphoma/Leukemia and lymphoma Open access 11 Sep 2013 43
33 A mass spectrometry-based approach to host cell protein identification and its application in a comparability exercise Veronika Reisinger, Hansjoerg Toll, Robert Ernst Mayer et al. · Analytical Biochemistry 17 Jun 2014 43
34 Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines Tina Jarc, Maša Novak, Neli Hevir et al. · Journal of Pharmacy and Pharmacology 3 Jun 2019 42
35 Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study Marco Matucci‐Cerinic, Yannick Allanore, Arthur Kavanaugh et al. · RMD Open Open access Nov 2018 41
36 A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial Kimberly Blackwell, Roman Donskih, C. Michael Jones et al. · The Oncologist Open access 18 Apr 2016 40
37 Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study Piotr Wiland, Sławomir Jeka, Eva Dokoupilová et al. · BioDrugs Open access 29 Oct 2020 38
38 Application of the GastroDuo as an in Vitro Dissolution Tool To Simulate the Gastric Emptying of the Postprandial Stomach Philipp Schick, Maximilian Sager, Franziska Wegner et al. · Molecular Pharmaceutics 8 Oct 2019 38
39 Randomized, Double-Blind Study Comparing Proposed Biosimilar La-Ep2006 with Reference Pegfilgrastim in Breast Cancer Nadia Harbeck, Oleg Nikolaevich Lipatov, Мона Александровна Фролова et al. · Future Oncology Open access 29 Mar 2016 38
40 HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours Karin Weigang-Köhler, Andrea Vetter, Ursula Thyroff‐Friesinger · Oncology Research and Treatment 2009 38
41 GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods Oliver von Richter, Lena Lemke, Halimu N. Haliduola et al. · Expert Opinion on Biological Therapy Open access 30 Jan 2019 36
42 Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial Fritz Sörgel, Ursula Thyroff‐Friesinger, Andrea Vetter et al. · BMC Clinical Pharmacology Open access 22 May 2009 36
43 Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study) Matti Aapro, Heinz Ludwig, Carsten Bokemeyer et al. · Annals of Oncology Open access 28 Oct 2016 35
44 Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study Janusz Jaworski, Marco Matucci‐Cerinic, Hendrik Schulze‐Koops et al. · Arthritis Research & Therapy Open access 28 May 2019 34
45 Biophysical Techniques for Characterizing the Higher Order Structure and Interactions of Monoclonal Antibodies Yatin R. Gokarn, Sanjeev Agarwal, Kelly K. Arthur et al. · ACS symposium series Conference paper 2015 34
46 A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective Cathelijne P. A. M. Kloks, C Berger, Pierre Cortez et al. · Journal of Immunological Methods 17 Jan 2015 34
47 Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients Edoardo Botteri, Andriy Krendyukov, Giuseppe Curigliano · European Journal of Cancer Review 8 Dec 2017 33
48 GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes Oliver von Richter, Andrej Skerjanec, Miguel Afonso Filipe et al. · British Journal of Clinical Pharmacology Open access 28 Oct 2016 33
49 Biosimilar granulocyte–colony‐stimulating factor for healthy donor stem cell mobilization: need we be afraid? Halvard B. Bonig, Petra S. A. Becker, Arnd Schwebig et al. · Transfusion Open access 26 Jun 2014 33
50 The structure-function relationship of disulfide bonds in etanercept William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter et al. · Scientific Reports Open access 15 Jun 2017 32

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.